# Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide

> **NCT00290953** · PHASE2,PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 432 (actual)

## Conditions studied

- Lung Cancer
- Pulmonary Neoplasms
- Small Cell Lung Cancer

## Interventions

- **DRUG:** SR48692

## Key facts

- **NCT ID:** NCT00290953
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 432 (ACTUAL)
- **Last updated:** 2008-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00290953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00290953, "Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00290953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*